A homogeneous conjugate for targeting and treating diseased cells wherein the
conjugate
comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer
drug is selected from the group consisting of heat sensitizers, photosensitizers
and apoptosis inducing compounds, a method for making such a conjugate, and methods
for using the conjugate. The targeting protein is preferably transferrin.